+++ Jetzt einfach und intuitiv in Kryptowährungen investieren! +++-w-
11.02.2020 07:15:00

Press Release: Novartis announces MET inhibitor -2-

9. CancerCare. Types and Staging of Lung Cancer. Available at:

https://www.lungcancer.org/find_information/publications/163-lung_cancer_101/268-types_and_staging.

Accessed December 13, 2019.

*FoundationOne(R)CDx is a registered trademark of Foundation Medicine,

Inc.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Anja von Treskow Rosemarie Yancosek

Novartis Global Media Relations Novartis Oncology Communications

+41 61 324 2279 (direct) +1 862 505 9021 (mobile)

+41 79 392 8697 (mobile) rosemarie.yancosek@novartis.com

anja.von_treskow@novartis.com mailto:anja.von_treskow@novartis.com

Eric Althoff

Novartis U.S. External Communications

+1 646 438 4335

eric.althoff@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052

Pierre-Michel Bringer +41 61 324 1065

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188 Cory Twining +1 862 778 3258

(END) Dow Jones Newswires

February 11, 2020 01:15 ET (06:15 GMT)